Chemistry does not observe the boundaries between industries. The same organic synthesis expertise that produces an active pharmaceutical ingredient for a cancer treatment can produce an active ingredient for crop protection. Hikal Limited, founded in Mumbai in 1988 by Jai Hiremath, is one of the few companies in the world that operates at the intersection of pharmaceutical and agricultural chemistry — manufacturing for both industries from the same base of technical capabilities.
Most chemical companies choose one lane. Pharmaceutical chemistry and crop protection chemistry each have their own regulatory frameworks, quality standards, customer bases, and competitive dynamics. Building expertise in both requires twice the investment in regulatory compliance, twice the range of customer relationships, and a scientific team comfortable working across therapeutic molecules and agrochemical active ingredients.
Hikal chose both. The company’s pharmaceutical division produces APIs, advanced intermediates, and contract manufacturing services for global pharmaceutical and biotech companies. The crop protection division produces active ingredients and intermediates for multinational agrochemical companies. In FY 2025, the pharmaceutical segment generated approximately 62% of revenue, with crop protection contributing the remaining 38%.
The strategic logic is diversification. When pharmaceutical markets soften — as they did globally in FY 2024, when inventory destocking and overcapacity in the chemical sector hit the industry — crop protection can provide stability. When agricultural commodity prices weaken, pharmaceutical demand can carry the business. The dual model does not eliminate cyclicality, but it reduces the amplitude.
Hikal operates five manufacturing facilities across India: two in Maharashtra (Taloja and Mahad), two in Gujarat (Panoli), and one in Karnataka (Jigani, Bengaluru). The company also maintains a dedicated research and technology centre in Pune that supports process development, analytical services, and new product development for both the pharmaceutical and crop protection businesses.
The manufacturing sites are designed for flexibility. Multi-purpose chemical reactors can be reconfigured for different products, allowing Hikal to serve both pharmaceutical and agrochemical clients from shared infrastructure. This flexibility is particularly valuable in the CDMO model, where client projects move through development phases that require different scales of production — from kilograms in the pilot phase to hundreds of tonnes at commercial scale.
In 2006, Hikal became the first Indian life-sciences company to receive the Responsible Care certification governed by the International Council of Chemical Associations — a recognition of the company’s environmental, health, and safety management systems. For a company handling complex chemical synthesis at industrial scale, this certification is not decorative; it reflects operational discipline that global pharmaceutical and agrochemical clients require of their contract manufacturing partners.
Hikal’s pharmaceutical business spans APIs and intermediates for both innovator and generic clients. The company provides contract development and manufacturing services that take client molecules from process development through to commercial-scale production. Key therapeutic areas include anti-infectives, cardiovascular, CNS, and animal health.
The crop protection business produces active ingredients and advanced intermediates for multinational agrochemical companies. Hikal’s chemistry capabilities in this segment include synthesis of complex heterocyclic compounds, which are increasingly important in next-generation crop protection products that target specific pests while minimizing environmental impact.
What connects the two businesses is process chemistry — the ability to design, optimise, and scale chemical reactions reliably. A chemist who can solve a synthesis problem for a pharmaceutical intermediate can often apply similar thinking to an agrochemical challenge. Hikal’s dual structure allows it to attract and retain scientists who work across both domains, creating a depth of expertise that single-industry companies cannot easily replicate.
Hikal’s revenue mix has shifted toward pharmaceuticals over the past several years, reflecting growing demand for contract manufacturing services from global pharma and biotech companies. The pharmaceutical segment grew 7.1% year-over-year in the first nine months of FY 2025, while the crop protection segment provided steady baseload revenue from long-standing relationships with multinational agrochemical clients.
Hikal’s five manufacturing sites across Maharashtra, Gujarat, and Karnataka provide a combined production capacity that serves clients across the pharmaceutical, biotech, and agrochemical industries. The Pune R&D centre employs scientists specialising in organic chemistry, process engineering, and analytical development. The company’s facilities are designed for multi-product, multi-scale operations — from early-stage development quantities through to commercial manufacture of hundreds of tonnes per year.
Sources: Hikal Limited Annual Reports FY2021 through FY2025. Hikal Limited Earnings Conference Call Transcripts. ICRA Rating Reports (March 2024, April 2025). Indian patent office records. International Council of Chemical Associations (ICCA) certification records.